SINTX Technologies Ships First Order of FleX SN-PEEK Composite
July 27 2021 - 9:00AM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or
the “Company”), an original equipment manufacturer of silicon
nitride ceramic for medical and non-medical applications, announced
today the first shipment of its new product, FleX SN-PEEK, which
will be used in orthopedic implants.
SINTX’s FleX SN-PEEK product started shipping on
July 20, 2021 and combines the unique bioactivity of silicon
nitride with the familiarity and properties of Zeniva PEEK, which
was supplied by Solvay (www.solvay.com), a global leader in
materials, chemicals, and solutions. The composite material has a
broad range of applications from spine surgery to joint
replacements to craniomaxillofacial medical devices. Based on data
from the Company’s silicon nitride, FleX SN-PEEK is expected to
facilitate faster bone healing, improve radiographic imaging, avoid
metal ion release in the body, and have broad-spectrum resistance
to infection compared to PEEK alone.
“The shipping of our new FleX SN-PEEK product is
a huge milestone for SINTX, and we couldn’t be more excited,” said
Dr. Sonny Bal, President, and CEO at SINTX Technologies. “We’re
continuing to leverage the osteogenic and antipathogenic properties
of silicon nitride for biomedical applications and believe this is
a superior product that has many benefits.”
Zeniva PEEK is a known biomaterial that has been
used worldwide and has many advantages including, favorable
material modulus, ease of manufacturing, established clinical
record, and a track record of use in orthopedics. SINTX believes
the combination of PEEK with silicon nitride’s osteogenic and
antipathogenic properties results in a truly innovative product,
FleX SN-PEEK.
“Our line of FleX SN-PEEK products opens doors
to new biomedical areas like craniomaxillofacial, and foot
osteotomy and fusion,” said Michael Marcroft, SINTX Vice President
of Business Development. “Surgeons are constantly looking for
materials and procedures that improve outcomes and reduce
complications, and our material fulfills that demand.”
The product launch is the result of SINTX’s
commitment to innovation. The Company looks forward to expanding
its customer base with this new and exciting platform. With its
experience in manufacturing spinal implants made of silicon nitride
and previous FDA approvals, SINTX sees ongoing attractive
opportunities in the biomedical market.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company presently manufactures
silicon nitride powders and components in its FDA registered, ISO
13485:2016 certified, and ASD9100D certified manufacturing
facility.
For more information on SINTX Technologies
or its silicon nitride material platform, please
visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things: market acceptance of the
rebranding of company products FleX SN; volatility in the price of
SINTX’s common stock; the uncertainties inherent in new product
development, including the cost and time required to commercialize
such product(s); market acceptance of our products once
commercialized; SINTX’s ability to raise funding and other
competitive developments. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management’s current
estimates, projections, expectations and beliefs. There can be no
assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in SINTX’s Risk Factors disclosure
in its Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other
filings with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Associate Director, Content and PR The Summit Group
abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2024 to Apr 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2023 to Apr 2024